Scientists have found a protein building up inside muscle cells that may help explain why type 2 diabetes takes hold in the first place.
Quick Take
- Researchers found a protein called Miro1 piles up in the muscle of people with obesity and type 2 diabetes.
- In mice and lab cells, removing Miro1 from muscle improved insulin response and energy production.
- Exercise lowered Miro1 levels in diabetic patients while also improving their insulin sensitivity.
- The findings come from a single new study, so human drug trials and independent repeat studies haven’t happened yet.
A New Suspect Found Inside Muscle Cells
A team led by researchers at Pennington Biomedical Research Center and the University of Oklahoma pinpointed a protein named Miro1 as a possible driver of insulin resistance. The study, published in Nature Communications on October 19, found Miro1 accumulates in skeletal muscle of people with obesity and type 2 diabetes. That matters because skeletal muscle soaks up most of the sugar we eat, and when it stops responding to insulin properly, blood sugar climbs.
Miro1 normally helps move mitochondria, the tiny engines inside cells that burn fuel for energy, around the muscle fiber. The study found that insulin is supposed to signal those mitochondria to dial back Miro1 production. In people with diabetes, that signal breaks down. The result is too much Miro1, poorly placed mitochondria, and a muscle cell that struggles to burn sugar efficiently.
Why Mice And Lab Cells Back Up The Theory
Finding more Miro1 in sick muscle only proves the two show up together. To test cause and effect, the team deleted the Miro1 gene specifically in mouse muscle and in lab-grown muscle cells. Both showed real improvement: better oxygen use, sharper insulin signaling, and higher glucose uptake, according to the published findings. That jump from observation to intervention is what separates a solid lead from a passing correlation.
John Kirwan, the study’s senior author, led the project alongside first author Elizabeth Heintz and co-corresponding author Christopher Axelrod. Pennington Biomedical’s announcement described removing Miro1 as something that “restored muscle insulin response” in the preclinical models tested. That’s an encouraging result, but it came from mice and cells, not from a drug given to diabetic patients. The next real test is whether a treatment aimed at human Miro1 can do the same thing safely.
Exercise Already Seems To Lower Miro1 Naturally
The human side of the study tracked patients with type 2 diabetes who went through an exercise program. Those who exercised saw Miro1 levels drop sharply, while a comparison group without the same training saw levels rise. The reported shift was a 64.3% change in the exercise group versus a 53.2% drop in the other direction, a gap researchers called statistically meaningful. Insulin sensitivity improved right alongside the Miro1 decline.
That doesn’t prove exercise works by lowering Miro1 specifically. Exercise changes dozens of things in the body at once, from inflammation to fat storage to how muscles respond to medication. Researchers can’t yet say Miro1 reduction is the reason exercise helps diabetic patients, only that the two move together in the data collected so far. Still, it adds another reason doctors have pushed physical activity as frontline diabetes treatment for decades.
What Still Needs To Happen Before This Becomes A Treatment
No drug currently exists that targets Miro1 in humans, and the study didn’t test one. The human portion of the research was observational, meaning it captured a snapshot in time rather than following people from healthy muscle through the slow slide into diabetes. Turning this into a treatment would likely require a muscle-specific approach, since Miro1 also plays roles in nerve cells and other tissues throughout the body.
A little-known protein could be a major culprit in type 2 diabetes. Buildup of Miro1 may drive insulin resistance; removing it restored muscle response in preclinical work, and exercise lowered its levels. https://t.co/2eTlIOE83b
— Drew Grimaldi (@Grimillionaire) November 9, 2026
Scientists outside the original team will need to repeat these experiments in different labs, with different patient groups, before Miro1 earns a spot on the short list of validated diabetes drug targets. That’s normal science, not a knock against this study. Given how many Americans live with type 2 diabetes and insulin resistance tied to obesity, a genuine new mechanism worth chasing is good news, even if the finish line is still years away.
Sources:
sciencedaily.com, nature.com, pmc.ncbi.nlm.nih.gov
